[IF-RT Alone Remains Gold Standard for Stage IA Nodular Lymphocyte-predominant Hodgkin Lymphoma]

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2016 May 20

PMID 27194138

Authors

Karoline Pilz

Christina Jentsch

Mechthild Krause

Affiliations

Soon will be listed here.

References

Wilder R, Schlembach P, Jones D, Chronowski G, Ha C, Younes A . European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002; 94(6):1731-8. DOI: 10.1002/cncr.10404. View

Wirth A, Yuen K, Barton M, Roos D, Gogna K, Pratt G . Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005; 104(6):1221-9. DOI: 10.1002/cncr.21303. View

Nicholas D, Harris S, Wright D . Lymphocyte predominance Hodgkin's disease--an immunohistochemical study. Histopathology. 1990; 16(2):157-65. DOI: 10.1111/j.1365-2559.1990.tb01084.x. View

Koh E, Tran T, Heydarian M, Sachs R, Tsang R, Brenner D . A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007; 2:13. PMC: 1847517. DOI: 10.1186/1748-717X-2-13. View

Cosset J, Henry-Amar M, Meerwaldt J . Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol. 1991; 2 Suppl 2:77-82. DOI: 10.1093/annonc/2.suppl_2.77. View

Pappa V, Norton A, Gupta R, Wilson A, Rohatiner A, Lister T . Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Ann Oncol. 1995; 6(6):559-65. DOI: 10.1093/oxfordjournals.annonc.a059244. View

Trudel M, Krikorian J, NEIMAN R . Lymphocyte predominance Hodgkin's disease. A clinicopathologic reassessment. Cancer. 1987; 59(1):99-106. DOI: 10.1002/1097-0142(19870101)59:1<99::aid-cncr2820590122>3.0.co;2-j. View

Schlembach P, Wilder R, Jones D, Ha C, Fayad L, Younes A . Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J. 2002; 8(5):377-83. DOI: 10.1097/00130404-200209000-00008. View

Hoppe R, Advani R, Ai W, Ambinder R, Aoun P, Bello C . Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012; 10(5):589-97. DOI: 10.6004/jnccn.2012.0061. View

10.

Ekstrand B, Lucas J, Horwitz S, Fan Z, Breslin S, Hoppe R . Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003; 101(11):4285-9. DOI: 10.1182/blood-2002-08-2644. View

11.

Hodgson D, Koh E, Tran T, Heydarian M, Tsang R, Pintilie M . Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer. 2007; 110(11):2576-86. DOI: 10.1002/cncr.23081. View

12.

Nogova L, Reineke T, Eich H, Josting A, Muller-Hermelink H, Wingbermuhle K . Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005; 16(10):1683-7. DOI: 10.1093/annonc/mdi323. View

13.

Rehwald U, Schulz H, Reiser M, Sieber M, Staak J, Morschhauser F . Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003; 101(2):420-4. DOI: 10.1182/blood.V101.2.420. View

14.

Eichenauer D, Plutschow A, Fuchs M, von Tresckow B, Boll B, Behringer K . Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. J Clin Oncol. 2015; 33(26):2857-62. DOI: 10.1200/JCO.2014.60.4363. View

15.

Diehl V, Sextro M, Franklin J, Hansmann M, Harris N, Jaffe E . Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999; 17(3):776-83. DOI: 10.1200/JCO.1999.17.3.776. View

16.

Nogova L, Reineke T, Brillant C, Sieniawski M, Rudiger T, Josting A . Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2007; 26(3):434-9. DOI: 10.1200/JCO.2007.11.8869. View

17.

Anagnostopoulos I, Hansmann M, Franssila K, Harris M, Harris N, Jaffe E . European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000; 96(5):1889-99. View